ICU Medical Q4 EBITDA Down 7%, Integration Delays Keep 2026 Target Below $500M
ICU Medical's Q4 Adjusted EBITDA fell 7% year-over-year, with deconsolidation of its IV Solutions unit and tariffs trimming $25 million. Completed integration of two Smiths Medical sites left 2026 EBITDA guidance below the original $500 million target, and tariffs are expected to shave about 2% of next-year revenue.
1. Q4 Financial Performance
ICU Medical reported a 7% decline in Adjusted EBITDA for Q4 2025, with a $25 million negative impact from the deconsolidation of the IV Solutions business and tariffs. Reported revenues fell 14% following the creation of the Otsuka-ICU joint venture and the deconsolidation of the IV Solutions unit.
2. Smiths Medical Integration and Guidance
The manufacturing integration of two large legacy Smiths Medical sites is complete, but integration challenges have delayed synergies and kept 2026 EBITDA guidance below the original $500 million target. Tariff headwinds are projected to reduce gross margins by approximately 2% of revenue next year.
3. Strategic Operations and Outlook
Management maintains mid-single-digit growth guidance for consumables and notes stable pump system placements, focusing on Duo and Solo in the US and the model 60 internationally. Structural changes to mitigate tariffs are underway, and a potential sale of the lower-margin Vital Care unit is being pursued with the goal of an EPS-neutral outcome and improved business profile.